Deconstructing Ecstasy: The Politics Of Mdma Research

References

• Adamson S. Through the Gateway of the Heart: Accounts of Experiences with MDMA and Other Empathogenic Substances. Four Trees Publications, San Francisco 1985
   Google Scholar
• Adamson S., Metzner R. The nature of the MDMA experience and its role in healing, psychotherapy and spiritual practice. Revision 1988; 10: 59–72
   Google Scholar
• Ali S. F., Newport G. D., Scallet A. C, Binienda Z., Ferguson S. A., Bailey J. R. Oral administration of MDMA produces selective 5-HT depletion in the non-human primate. Neurotoxicol. Teratol. 1993; 15: 91–96
   PubMed Web of Science ®Google Scholar
• Azmitia E. C, Murphy R. B., Whitaker-Azmitia P. M. MDMA (Ecstasy) effects on cultured serotonergic neurons: evidence for Ca dependent toxicity linked to release. Brain Res. 1990; 510: 97–103
   PubMed Web of Science ®Google Scholar
• Azmitia E. C., Whitaker-Azmitia P. M. Awakening the sleeping giant: anatomy and plasticity of the brain serotonergic system. J. Clin. Psychiatry 1991; 52(suppl)4–16
   PubMedGoogle Scholar
• Bakalar J., Grinspoon J. B. Testing psychotherapies and drug therapies: the case of psychedelic drugs. Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA, S. J. Peroutka. Kluwer, Holland 1990; 37–52
   Google Scholar
• Battaglia G., Yeh S. Y., DeSouza E. B. MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol. Biochem. Behav. 1988; 29: 269–274
   PubMed Web of Science ®Google Scholar
• Beck J. Ecstasy and the rave scene: historical and cross-cultural perspectives. CEWG 1993; 424–431
   Google Scholar
• Beck J., Morgan P. A. Designer drug confusion: a focus on MDMA. J. Drug. Education 1986; 16: 287–302
   PubMed Web of Science ®Google Scholar
• Beck J., Rosenbaum M. Pursuit of Ecstasy: The MDMA Experience. State University of New York Press, Albany, New York 1994
   Google Scholar
• Bolla K. I., McCann U. D., Ricaurte G. A. Memory impairment in abstinent MDMA (“Ecstasy”) users. Neurology 1998; 51: 1532–1537
   PubMed Web of Science ®Google Scholar
• Brody S., Krause, Veit R., Rau H. Cardiovascular autonomic dysregulation users of MDMA (“ecstasy”). Psychopharmacol 1998; 136: 390–393
   Web of Science ®Google Scholar
• Broening H. W., Bowyer J. F., Slikker W. Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant 3,4-methylenedioxy-methampethamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. J. Pharmacol. Exp. Ther. 1995; 275: 325–333
   PubMed Web of Science ®Google Scholar
• Buchanan J. F., Brown C. R. Designer drugs: a problem in clinical toxicology. Med. Toxicol. 1988; 3: 1–17
   Google Scholar
• Buck A., Gucker P., Vollenweider F. X., Burger C. Evaluation of serotonergic transporter using PET and HC-(+)-McN-5652: assessment of methods. J. Cerebral Blood Flow Metabolism 2000, in press.
   Web of Science ®Google Scholar
• Burchett S. A., Bannon M. J. Serotonin, dopamine and norepinephrine transporter mRNAs: heterogeneity of distribution and response to ‘binge’ cocaine administration. Molecular Brain Res. 1997; 49: 95–102
   PubMedGoogle Scholar
• Burger A. J., Sherman H. B., Charlamb M. J., Kim J., Asinas L. A., Flickner S. R., Blackburn G. L. Low prevalence of valvular heart disease in 226 phenterminefenfluramine protocol subjects prospectively followed for up to 30 months. J. Am. Coll. Cardiol. 1999; 34: 1153–1158
   PubMed Web of Science ®Google Scholar
• Caccia S., Ballabio M., Guiso G., Rochetti M., Garattini S. Species differences in the kinetics of metabolism of fenfluramine isomers. Arch. Int. Phar-macodyn. 1982; 258: 15–28
   PubMedGoogle Scholar
• Caccia S., Anelli M., Ferrarese A., Fracasso C., Garattini S. The role of d-norfenluramine in the indole-depleting effect of d-fenfluramine in the rat. Eur. J. Pharmacol. 1993; 223: 71–77
   Google Scholar
• Capdevila M. MDMA o el Extasis Quimico. Los Libros, Barcelona
   Google Scholar
• De La Liebre De Marzo., Ceccherelli F., Costa C, Ischia S., Ischia A., Giron G., Alletri G. Cerebral tryptophan metabolism in humans in relation to malignant pain. Fund. Neurol. 1989; 4: 341–353
   PubMedGoogle Scholar
• Chappell S., Mordenti J. Extrapolation of toxicological and pharmacological data from animals to humans. Advances in Drug Research, B. Tests. Academic Press, San Diego 1991; 1–116
   Google Scholar
• Colado M. I., Murray T. K., Green A. R. 5-HT loss in rat brain following 3,4 methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br. J. Pharmacol. 1993; 108: 583–589
   PubMed Web of Science ®Google Scholar
• Colado M. I., Williams J. L., Green A. R. The hyperthermic and neurotoxic effects of ‘Ecstasy’ (MDMA) and 3,4-methylenedioxyampethamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br. J. Pharmacol. 1995; 115: 1281–1289
   PubMed Web of Science ®Google Scholar
• Collin M. Altered State: The Story of Ecstasy Culture and Acid House. Serpent's Tail, London 1998
   Google Scholar
• Costa C, Ceccherelli F., Bettero A., Marin G., Mancusi L., Allegri G. Tryptophan, serotonin and5-hydroxyindoleacetic acid levels in human CSFin relation to pain. Progress in Tryptophan and Serotonin Research, H. G. Schlossberger, W. Kochen, B. Linzen, H. Steinhart, 1984; 413–416
   Google Scholar
• Cuomo J. J., Dyment P. G., Gammino V. M. Increasing use of “ecstasy” (MDMA) and other hallucinogens of a college campus. J. Amer. College Health Assoc 1994; 42: 271–274
   Google Scholar
• Curran H. V. Is ecstasy (MDMA) a human neurotoxin?. Novartis Foundation Conference, London, December, 4, 1998
   Google Scholar
• Curran H. V., Travill R. A. Mood and cognitive effects of 3,4-methylene-dioxymethamphetamine (MDMA, ‘ecstasy’): weekend ‘high’ followed by mid-week low. Addiction 1997; 92: 821–831
   PubMed Web of Science ®Google Scholar
• Dalgarno P. J., Shewan D. Illicit use of ketamine in Scotland. J. Psychoactive Drugs 1996; 28: 191–199
   PubMed Web of Science ®Google Scholar
• DeRios M. D., Grob C. S. Hallucinogens, suggestibility and adolescence in cross-cultural perspective. Yearbook Ethnomedicine 1994; 3: 113–132
   Google Scholar
• Derome-Tremblay M., Nathan C. Fenfluramine studies. Science 1989; 243: 991
   PubMed Web of Science ®Google Scholar
• Doblin R. MAPS MDMA analysis project. MAPS 1996; 6: 11–13
   Google Scholar
• Dowling G. P., McDonough E. T., Bost R. O. “Eve” and “ecstasy”: a report of five deaths associated with the use of MDEA and MDMA. JAMA 1987; 257: 1615–1617
   PubMed Web of Science ®Google Scholar
• Downing J. The psychological physiological effects of MDMA on normal volunteers. J. Psychoactive Drugs 1986; 18: 335–339
   PubMed Web of Science ®Google Scholar
• Eisner B. Ecstasy: The MDMA Story. Ronin Publishing, Berkeley 1989
   Google Scholar
• Eliade M. Shamanism: Archaic Techniques of Ecstasy. Librarie Payot, Paris 1951, Ellison G. The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of dementias Brain Res. Rev. 1995 20 250–267Erowid E. (1998). Comments on MDMA neurotoxicity study: a prospective guinea pig. http://www.erowid.org?chernicals/mdma/mdma-journal3/mdma-journal3-comrnent3.shtml
   Google Scholar
• Erowid E. MDMA neurtoxicity study: questioning the correlation between increased MDMA use and decreased binding-an analysis of figure 4 of the McCann-Ricaurte MDMA study results. 1998b, http://www.erowid.org/chemicals/mdma/ mdmaJournal3-statistics.shtml
   Google Scholar
• Furnari C, Ottaviano V., Rosati F., Tondi V. Identification of 3,4- methylenedioxymethamphetamine analogs encountered in clandestine tablets. Forensic Science International 1998; 92: 49–58
   PubMed Web of Science ®Google Scholar
• Gasser P. Die psycholytische psychotherapie in der Schweiz (1988–1993). Jahrbuchfur Transkulturelle Medizin und Psychotherapie 1995a; 6: 143–162
   Google Scholar
• Gasser P. The psycholytic therapy in Switzerland from 1988–1993: a follow-up study. MAPS 1995b; 5: 3–7
   Google Scholar
• Gijsman G., Vrekes R., van Gervan J., Cohen A. MDMA study. Neuro psychopharmacol 1999; 21: 597
   Google Scholar
• Greer G., Tolbert R. Subjective reports of the effects of MDMA in a clinical setting. J. Psychoactive Drugs 1986; 18: 319–327
   PubMed Web of Science ®Google Scholar
• Grinspoon L., Bakalar J. B. Psychedelic Drugs Reconsidered. Basic Books, New York 1979
   Google Scholar
• Grinspoon L., Bakalar J. B. Can drugs be used to enhance the psychotherapeutic process. Am. J. Psychotherapy 1986; 40: 393–404
   PubMed Web of Science ®Google Scholar
• Grob C. S. Psychiatric research with hallucinogens: what have we learned. Heffter. Rev. Psychedelic Researh 1998; 1: 8–20
   Google Scholar
• Grob C. S., DeRios M. D. Adolescent drug use in cross-cultural perspective. J. Drug Issues 1992; 22: 121–138
   Web of Science ®Google Scholar
• Grob C. S., Poland R. E. MDMA. Substance Abuse: A Comprehensive Textbook Third Edition, J. H. Lowinson, P. Ruiz, R. B. Millman, J. G. Langrod. Williams and Wilkins, Baltimore 1997; 269–275
   Google Scholar
• Grob C. S., Bravo G. L., Walsh R. N. Second thoughts on 3,4-methylenedioxymethamphetamine (MDMA) neurotoxicity. Arch. Gen. Psychiatry 1990; 47: 288
   PubMed Web of Science ®Google Scholar
• Grob C. S., Bravo G. L., Walsh R. N., Liester M. B. The MDMA- neurotoxicity controversy: implications for clinical research with novel psychoactive drugs. J. Nerv. Menu Dis. 1992; 180: 355–356
   PubMed Web of Science ®Google Scholar
• Grob C. S., Poland R. E., Chang L., Ernst T. Psychobiologic effects of 3,4- methylenedioxymethamphetamine in humans: methodological considerations and preliminary findings. Behav. Brain Research 1996; 73: 103–107
   PubMed Web of Science ®Google Scholar
• Harrington R. D., Woodward J. A., Hooton T. M., Horn J. R. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch. Intern. Med. 1999; 159: 2221–2224
   PubMed Web of Science ®Google Scholar
• Harris Research Center. Young peoples poll. 1992
   Google Scholar
• Harris D., Baggott Jones R. T., Mendelson J. MDMA pharmacokinetics and physiological and subjective effects in humans. CPDD 1999; 59
   Google Scholar
• Harvey J. A., McMaster S. E., Yunger L. M. p-Chloroamphetamine: selective neurotoxic action in brain. Science 1975; 187: 841–843
   PubMed Web of Science ®Google Scholar
• Hatzidimitriou G., McCann U. D., Ricaurte G. A. Altered serotonin innervation patterns in the forebrain of monkeys treated with MDMA seven years previously: factors influencing abnormal recovery. J. Neurosci. 1999; 191: 5096–5107
   Google Scholar
• Heinz A., Higley J. D., Gorey J. G., Saunders R. C, Jones D. W., Hommer D., Zajicek K., Suomi S. J., Lesch K. P., Weinberger D. R., Linnoila M. In vivo association between alcohol intoxication, aggression, and serotonin transporter availability in nonhuman primates. Am. J. Psychiatry 1998; 155: 1023–1028
   PubMed Web of Science ®Google Scholar
• Henry J. A., Jeffreys K. J., Dawling S. Toxicity and deaths from 3, 4 methlyenedioxymethamphetamine (“ecstasy”). Lancet 1992; 340: 384–387
   PubMed Web of Science ®Google Scholar
• Hekmatpanah C. R., Peroutka S. J. 5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxymetham-phetamine and related agents. Eur. J. Pharmacol. 1990; 177: 95–98
   PubMed Web of Science ®Google Scholar
• Hewitt K. E., Green A. R. Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA (“Ecstasy”). Neuropharmacol. 1994; 33: 1589–1595
   PubMed Web of Science ®Google Scholar
• Inciyan E. Ecstasy's high-risk agenda. The Guardian 2000; 24
   Google Scholar
• Jansen K. L. R. Ecstasy (MDMA) dependence. Drug Alcohol Dependence 1998; 53: 121–124
   Web of Science ®Google Scholar
• Johnson M. P., Nichols D. E. Comparative serotonin neurotoxicity of the steroisomers of fenfluramine and norfenfluramine. Pharmacol. Biochem. Behav. 1990; 36: 105–109
   PubMed Web of Science ®Google Scholar
• Karel R. Fluoxetine may protect against MDMA neurotoxicity. Psychiatric News 1993; 6
   Google Scholar
• Krystal J. H., Price L. H., Opsahl C, Ricaurte G. A., Heninger G. R. Chronic 3, 4 methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function. Am. J. Drug Alcohol Abuse 1992; 18: 331–341
   PubMed Web of Science ®Google Scholar
• King L. A. Comments. Novartis Foundation Conference: Is Ecstasy (MDMA) A Human Neurotoxin?, London, December, 4, 1998
   Google Scholar
• Kuikka J. T., Ahonen A. K. Letter on toxic effect of MDMA on brain serotonin neurons. Lancet 1999; 353: 1269
   PubMedGoogle Scholar
• Kuroda Y., Watanabe Y., McEwen B. S. Tianeptine decreases both serotonin transporter mRNA and binding sites in rat brain. Eur. J. Pharmacol. 1994; 268: R3–R5
   Web of Science ®Google Scholar
• Lawn J. C. Schedules of controlled substances: scheduling of 3,4-methylenediox-ymethampehtamine (MDMA) into schedule I. Federal Register 1986; 51: 36552–36560
   Google Scholar
• Lesch K. P., Aulakh C. S., Wolozin B. L., Tolliver T. J., Hill J. L., Murphy D. L. Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants. Molecular Brain Res. 1993; 17: 31–35
   PubMedGoogle Scholar
• Lieberman J., Aghajanian G. Caveat emptor: researcher beware. Neuropsy-chopharmacol. 1999; 21: 472
   Web of Science ®Google Scholar
• Malberg J. E., Seiden L. S. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetmaine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J. Neurosci. 1998; 18: 5086–5094
   PubMed Web of Science ®Google Scholar
• Manchanda S., Connolly M. J. Cerebral infarction in association with ecstasy abuse. Postgrad Med. J. 1993; 69: 874–879
   PubMed Web of Science ®Google Scholar
• Marchant M. C, Breen M. A., Wallace D., Bass S., Taylor A. R., Ings R. M. J., Campbell B. Comparative biodisposition and metabolism of 14C-(+/-)-fenfluramine in mouse, rat, dog and man. Xenobiotica 1992; 12: 1251–1266
   Google Scholar
• Mas M., Farre M., De La Torre R., Roset P. N., Ortuno J., Segura J., Cami J. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4- methylenedioxymethamphetamine in humans. J. Pharmacol Exp. Ther. 1999; 290: 136–145
   PubMed Web of Science ®Google Scholar
• Matthews A., Jones C. Spate of British ecstasy deaths puzzles experts. Int. J. Drug Policy 1992; 3: 4
   Google Scholar
• McCann U. D., Ricaurte G. A. On the neurotoxicity of MDMA and related amphetamine derivatives. J. Clin. Psychopharmacol. 1995; 15: 295–296
   Web of Science ®Google Scholar
• McCann U. D., Ricaurte G. A. Caveat emptor: editors beware. Neuropsy- chopharmacol 2000, in press.
   Google Scholar
• McCann U., Hatzidimitriou G., Ridenour A., Fischer C, Yuan J., Katz J., Ricaurte G. Dexfenfiuramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated. J. Pharmacol. Exp. Ther. 1994; 269: 792–798
   PubMed Web of Science ®Google Scholar
• McCann U. D., Mertl M., Eligulashvili V., Ricaurte G. A. Cognitive performance in 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) users: a controlled study. Psychpharmacol. 1999; 143: 417–425
   PubMed Web of Science ®Google Scholar
• McCann U. D., Szabo Z., Scheffel U., Dannals R. F., Ricaurte G. A. Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings. Lancet 1998; 352: 1433–1437
   PubMed Web of Science ®Google Scholar
• McEntee W. J., Crook T. H. Serotonin, memory and the aging brain. Psychopharmacol. 1991; 103: 143–149
   PubMed Web of Science ®Google Scholar
• McKenna D. J., Peroutka S. J. Neurochemistry and neurotoxicity of 3, 4-methylenedioxymethamphetamine. J. Neurochem. 1990; 54: 14–22
   PubMed Web of Science ®Google Scholar
• Molliver M. E., Berger U. V., Mamounas L. A., Molliver D. C, O'Hearn E., Wilson M. A. Neurotoxicity of MDMA and related compounds: anatomic studies. Ann. NY. Acad. Sci. 1990; 600: 640–664
   Web of Science ®Google Scholar
• Nelson K. T. MDMA and memory impairment: proven or not?. MAPS 1999; 9(3)6–8
   Google Scholar
• Newmeyer J. A. X at the crossroads. J. Psychoactive Drugs 1993; 25: 341–342
   PubMed Web of Science ®Google Scholar
• O'Callaghan J. P. Commentary on article by Ricaurte and colleagues. MAPS 1995; 6(1)13
   Google Scholar
• O'Callaghan J. P., Miller D. B. Quantification of reactive gliosis as an approach to neurotoxicity assessment. Assessing Neurotoxicity of Drugs of Abuse. National Institute on Drug Abuse Monograph 136, L. Erinoff. U.S. Government Printing Office, Washington, D.C 1993; 188–212
   Google Scholar
• O'Callaghan J. P., Miller D. B. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 1994; 270: 741–751
   PubMed Web of Science ®Google Scholar
• Parrott A. Is ecstasy (MDMA) a human neurotoxin?. Novartis Foundation Conference, London, December, 4, 1998
   Google Scholar
• Peroutka S. J. Incidence of recreational use of 3,4 methlenedioxymethampheta- mine (MDMA, “ecstasy”) on an undergradulate campus. New England J. Med. 1987; 317: 1542–1543
   PubMed Web of Science ®Google Scholar
• Peroutka S. J. Relative insensitivity of mice to 3,4-methylenedioxymethamphet- amine neurotoxicity. Res. Commun. Subs. Abuse 1988; 9: 193–206
   Google Scholar
• Pletscher A., Burkar W. P., Bruderer H., Gey K. F. Decrease of cerebral 5-hydroxytryptamine and 5-hydroxyindolacetic acid by arylalkylamine. Life Sci. 1963; 11: 828–833
   Google Scholar
• Price L. H., Ricaurte G. A., Krystal J. H., Henninger G. R. Neuroendocrine and mood responses to intravenous 1-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Arch. Gen. Psychiatry, 46: 20–22
   PubMed Web of Science ®Google Scholar
• Randall T. Ecstasy-fuled “rave” parties become dances of death for English youths. JAMA 1992; 268: 1505–1506
   PubMed Web of Science ®Google Scholar
• Rezvani A. H., Garges P. L., Miller D. B., Gordon C. J. Attenuation of alcohol consumption by MDMA (Ecstasy) in two strains of alcohol-preferring rats. Pharmacol. Biochem. Behav. 1992; 43: 103–110
   PubMed Web of Science ®Google Scholar
• Ricaurte G., Bryan G., Strauss L., Seiden L., Schuster C. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 1985; 229: 986–988
   PubMed Web of Science ®Google Scholar
• Ricaurte G. A., Finnegan K. T., Irwin I., Langston J. W. Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations. Ann. NY Acad. Sci. 1990; 600: 699–708
   PubMed Web of Science ®Google Scholar
• Riedlinger T. J., Riedlinger J. E. Psychedelic and entactogenic drugs in the treatment of depression. J. Psychoactive Drugs 1994; 26: 41–55
   PubMed Web of Science ®Google Scholar
• Robinson T. E., Castandea E., Whishaw I. Q. Effects of cortical serotonin depletion induced by 3,4-methylenedioxymethamphetamine (MDMA) on behavior, before and after additional cholinergic blockade. Neuropsychopharmacol. 1993; 8: 77–85
   PubMed Web of Science ®Google Scholar
• Romano A. G., Harvey J. A. MDMA enhances associative and nonasso- ciative learning in the rabbit. Pharmacol. Biochem. Behav. 1993; 47: 289–293
   Web of Science ®Google Scholar
• Sanders-Bush E., Bushing J. A., Sulser F. Long-term effects of p-chloro- amphetamine and related drugs of central serotonergic mechanisms. J. Pharmacol Exp. Ther. 1975; 192: 33–40
   PubMed Web of Science ®Google Scholar
• Saunders N. E is for Ecstasy. Saunders, London 1993, Saunders, N. (1995). Ecstasy and the dance culture. London: Saunders.
   Google Scholar
• Saunders N., Doblin R. Ecstasy: Dance Trance and Transformation. Quick American Archives, Oakland, California 1996
   Google Scholar
• Schifano F., DiFuria L., Forz G., Minicuci N., Bricolo R. MDMA (‘ecstasy’) consumption in the context of polydrug abuse: a report on 150 patients. Drug Alcohol Dependence 1998; 52: 85–90
   PubMed Web of Science ®Google Scholar
• Schiller N. B. Fen/phen and valvular heart disease: if it sounds too bad to be true, perhaps it isn't. J. Am. Coll. Cardiol. 1999; 34: 1159–1162
   PubMed Web of Science ®Google Scholar
• Schmidt C. J. Neurotoxicity of the psychedelic amphetamine, methylenedioxy- methamphetamine. J. Pharmacol. Exp. Ther. 1987; 240: 1–7
   PubMed Web of Science ®Google Scholar
• Schmidt C. J., Taylor V. L. Depression of rat brain tryptophan hydroxylase following the acute administration of methylenedioxymethamphetamine. Biochem. Pharmacol. 1987; 36: 4095–4102
   PubMed Web of Science ®Google Scholar
• Schmidt C. J., Abbate G. M., Black C. K., Taylor V. L. Selective 5-HT2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats. J. Pharmacol. Exp. Ther. 1990; 255: 478–483
   PubMed Web of Science ®Google Scholar
• Schultes R. E., Hofmann A. Plants of the Gods: Their Sacred, Healing and Hallucinogenic Powers. Healing Arts Press, Rochester, Vermont 1992
   Google Scholar
• Sferios E. Report from DanceSafe: laboratory analysis program reveals DXM tablets sold as “ecstasy”. MAPS Bull 1999; 9(4)47
   Google Scholar
• Sharkey A. Sorted or distorted. The Guardian 1996; 26: 2–4
   Google Scholar
• Shewan D., Dalgarno P., King L. A. Tablets often contain substances in addition to, or instead of, ecstasy. Lancet 1996; 313: 423–424
   Google Scholar
• Shulgin A. T. The background and chemistry of MDMA. J. Psychoactive Drugs 1986; 18: 291–304
   PubMed Web of Science ®Google Scholar
• Shulgin A. T. History of MDMA. Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA, S. J. Peroutka. Kluwer, Holland 1990; 1–20
   Google Scholar
• Shulgin A. T., Nichols D. E. Characterization of three new psychotomimetics. The Psychopharmacology of Hallucinogens, R. Stillman, R. Willete. Pergamon Press, New York 1978; 74–83
   Google Scholar
• Shulgin A., Shulgin A. PIHKAL. Transform Press, Berkeley 1991
   Google Scholar
• Slikker W., Ali S. F., Scallet A. C, Frith C. H., Newport G. D., Bailey J. R. Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol. Appl. Pharmacol. 1988; 94: 448–457
   PubMed Web of Science ®Google Scholar
• Slikker W. J., Holson R. R., Ali S. F., Kolta M. G., Paule M. G., Scallet A. C, McMillan D. E., Bailey J. R., Hong J. S., Scalzo R. M. Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. Neurotoxicoi 1989; 10: 529–542
   PubMed Web of Science ®Google Scholar
• Sprague J. E., Nichols D. E. The monoamine oxidase-B inhibitor 1-deprenyl protects against 3,4-methylenedioxymethampehtmaine-induced lipid peroxidation and long-term serotonergic deficits. J. Pharmacol. Exp. Ther. 1995; 273: 667–673
   PubMed Web of Science ®Google Scholar
• Sprague J. E., Everman S. L., Nichols D. E. An integrated hypothesis for the serotonergic axonal loss induced by 3, 4 methylenedioxymethamphetamine. NeuroToxicol. 1998; 19: 427–442
   PubMed Web of Science ®Google Scholar
• Suomi S. J. Attachment in rhesus monkeys. Handbook of Attachment: Theory, Research and Clinical Applications, J. Cassidy, P. R. Shaver. Guilford Press, New York 1999; 181–197
   Google Scholar
• Sylvester R. Ecstasy: the truth. The Sunday Telegraph 1995; 19: 24
   Google Scholar
• Tancer M., Schuster C. R. Serotonin and dopamine system interactions in the reinforcing properties of psychostimulants: a research strategy. MAPS 1997; 7(3)5–11
   Google Scholar
• Tancer M., Johanson C. E. Subjective responses to MDMA and mCPP: A human dose run-up study. CPDD 1999; 160
   Google Scholar
• Vollenweider F., Gamma A., Liechti M., Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA (ecstasy) in MDMA-naive healthy volunteers. Neuropsychopharmacol. 1998; 19: 241–251
   PubMed Web of Science ®Google Scholar
• Vollenweider F. X., Gamma A., Liechti M., Huber T. Is a single dose of MDMA harmless. Neuropsychopharmacol. 1999; 21: 598–600
   PubMed Web of Science ®Google Scholar
• Watanabe Y., Sakai R. R., McEwen B. S., Mendelson S. Stress and antidepressant effects on hippocampal and cortical 5-HT1A and 5-HT2 receptors and transport sites for serotonin. Brain Res. 1993; 615: 87–94
   PubMed Web of Science ®Google Scholar
• Winstock A. R., King L. A. Tablets often contain substances in addition to, or instead of, ecstasy, such as ketamine. Lancet 1996; 313: 423–424
   Google Scholar
• Wolff K., Hay A. W. M., Sherlock K., Conner M. Contents of “ecstasy”. Lancet 1996; 346: 1100–1101
   Web of Science ®Google Scholar
• Young F. Opinion and recommended ruling, findings of fact, conclusions of law and decision of administrative law judge: submitted in the matter of MDMA scheduling. U.S. Drug Enforcement Administration Docket. 1986; 84–88
   Google Scholar
• Ziporyn T. A growing industry and menace: makeshift laboratory's designer drugs. JAMA 1986; 256: 3061–3063
   PubMed Web of Science ®Google Scholar